识别和向与POLQ相关的遗传性结肠直肠癌
Ning Xu1,2, Deng-Feng Zhang3, Xiao-Xiao Shi4
1The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China.
概括
一个新的基因,聚合酶 θ (POLQ),与遗传性结直肠癌有关. 在POLQ的突变导致高瘤突变负担和耐药性,但POLQ抑制剂显示出治疗的希望.
科学领域:
- 遗传学 遗传学 是一个
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 遗传性结直肠癌 (CRC) 综合征尚未完全理解,许多病例缺乏已知的遗传原因.
- 识别基因驱动因素对于理解CRC病原体和开发向疗法至关重要.
研究的目的:
- 在遗传性结直肠癌中识别致病突变.
- 探索针对新型治疗策略的鉴定突变的潜力.
主要方法:
- 来自遗传性CRC和多重症家族的个体的整体外体序列测序.
- 在体内和体外测定以评估突变对瘤发生的影响.
- 对零星CRC病例的查和对潜在的遗传CRC的扩大队列.
主要成果:
- 在多个CRC家族中发现了聚合酶 θ (POLQ) 基因的生殖基因突变 (p.Arg1953X).
- 这种POLQ突变导致 θ介导末端结合 (TMEJ) 的过度激活,导致高瘤突变负担和对破坏DNA的抗药性.
- 在临床前模型中,使用POLQ抑制剂 (novobiocin) 治疗抑制了TMEJ,并恢复了对DNA损伤的敏感性.
结论:
- POLQ被确定为遗传性结直肠癌中的致病基因,定义了一个由TMEJ过度激活驱动的新的POLQ型CRC.
- 查POLQ突变可以帮助早期诊断和个性化治疗遗传性CRC.
- 需要进一步的临床验证,以确认针对CRC中的POLQ的治疗潜力.
更多相关视频
05:58Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
Published on: August 20, 2018
11.0K
07:35Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection
Published on: June 8, 2020
7.0K
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129